Risk assessment for prevention of morbidity and mortality: Lessons for pressure ulcer prevention

Journal of Tissue Viability

Volumn 17, Issue 4, 2008, Pages 115-120

  Reynolds, T M ^a,b  

^a QUEEN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA1 GLYCOPROTEIN; C REACTIVE PROTEIN; PREALBUMIN;

ARTICLE; DECUBITUS; DISEASE COURSE; FLOTATION BED; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HUMAN; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST;

ALGORITHMS; CARDIOVASCULAR DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION TREES; DISCRIMINANT ANALYSIS; DOWN SYNDROME; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MORBIDITY; NURSING ASSESSMENT; PRACTICE GUIDELINES AS TOPIC; PRESSURE ULCER; PRIMARY PREVENTION; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 67049098010     PISSN: 0965206X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtv.2007.09.005     Document Type: Article

References (33)

1. Fontana R.S., Sanderson D.R., Woolner L.B., Taylor W.F., Miller W.E., Muhm J.R., et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 67 Suppl. 4 (1991) 1155-1164
2. Tannock I.F. Eradication of a disease: how we cured asymptomatic prostate cancer. Lancet Oncol (2000 May) 17-18
3. JBS2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 Suppl. 5 (2005) 1-52
4. Anderson K.M., Odell P.M., Wilson P.W.F., and Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 121 (1991) 293-298
5. Reynolds T.M., Twomey P., and Wierzbicki A.S. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 9 (2002) 183-190
6. Wierzbicki A., Reynolds T., Gill K., Alg S., and Crook M. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J Cardiovasc Risk 7 (2000) 63-73
7. Reynolds T.M., Twomey P., and Wierzbicki A.S. Concordance evaluation of the coronary risk scores: implications for CHD risk screening. Curr Med Res Opin 20 (2004) 811-818
8. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med 347 (2002) 1557-1565
9. Wilson P.F., Nam B.-H., Pencina M., D'Agostino R., Benjamin E.J., and O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham study. Arch Intern Med 165 (2005) 2473-2478
10. Folsom A.R., Chambless L.E., Ballantyne C.M., Coresh J., Heiss G., Wu K.K., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med 166 (2006) 1368-1373
11. Kumana C.R., Cheung B.M.Y., and Lauder I.J. Gauging the impact of statins using number needed to treat. J Am Med Assoc 282 (1999) 1899-1901
12. Oliver S.E., Gunnel D., and Donovan J.L. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet 355 (2000) 1788-1789
13. Lu-Yao G., Albertsen P.C., Stanford J.L., Stukel T.A., Walker-Corkery E.S., and Barry M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 325 (2002) 740-745
14. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng/milliliter. N Engl J Med 350 (2004) 2239-2246
15. Higashihara E., Nutahara K., Kojima M., Okegawa T., Miura I., Miyata A., et al. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol 156 (1996) 1964-1968
16. Reynolds T., and Penney M. The mathematical basis of multivariate risk analysis: with special reference to screening for Down's syndrome associated pregnancy. Ann. Clin. Biochem 27 (1990) 452-458
17. Reynolds T. Down's syndrome screening is unethical: views of today's ethics committees. J Clin Pathol 56 (2003) 268-270
18. Wald N., Cuckle H., Densem J., Nanchahal K., Royston P., Chard T., et al. Maternal serum screening for Down's syndrome in early pregnancy. Br Med J 297 (1988) 883-887
19. Reynolds T., John R., and Spencer K. The use of unconjugated estriol in Down syndrome screening is unproven. Clin Chem 39 (1993) 2023-2025
20. Wilson J.M., and Jungner G. Principles and practice of screening for disease (1968), World Health Organisation, Geneva Public Health Paper Number 34
21. Carter H.B. Prostate cancer in men with low PSA levels - must we find them?. N Engl J Med 350 (2004) 2292-2294
22. Anthony D., Reynolds T., and Russell L. The role of hospital-acquired pressure ulcer in length of stay. Clin Eff Nurs 8 (2004) 4-10
23. Grey J.E., Enoch S., and Harding K.G. ABC of wound healing: pressure ulcers. Br Med J 332 (2006) 472-475
24. Russell L.J., Reynolds T.M., Park C., Rithalia S., Gonsalkorale M., Birch J., et al. Randomized clinical trial comparing 2 support surfaces: results of the prevention of pressure ulcers study. Adv Skin Wound Care 16 (2003) 317-327
25. Nixon J., Cranny G., Iglesias C., Nelson A., Hawkins K., Phillips A., et al. Randomised controlled trial of alternating pressure mattresses compared with alternating pressure overlays for the prevention of pressure ulcers: PRESSURE (pressure relieving support surfaces) trial. Br Med J 332 (2006) 1413-1415
26. Russell L., Reynolds T., Towns A., Worth W., Greenman A., and Turner R. Randomized comparison trial of the RIK and Nimbus 3 mattresses. Br J Nurs 12 (2003) 254-259
27. National Institute for Clinical Excellence. Inherited clinical guidance B: pressure ulcer risk assessment and prevention (2001), NICE, London
28. Schoonhoven L., Haalboom J.R.E., Bousema M.T., Algra A., Grobbee D.E., Grypdonck M.H., et al. Prospective cohort study of routine use of risk assessment scales for prevention of pressure ulcers. Br Med J 325 (2002) 797-801
29. Anthony D., Reynolds T., and Russell L. A regression analysis of the Waterlow score in pressure ulcer risk assessment. Clin Rehabil 17 (2003) 216-233
30. Anthony D., Russell L., and Reynolds T. An investigation into the use of serum albumin in pressure sore prediction. J Adv Nurs 32 (2000) 359-365
31. Reynolds T.M., Stokes A., and Russell L. Assessment of a prognostic biochemical indicator of nutrition and inflammation for identification of pressure ulcer risk. J Clin Path 59 (2006) 308-310
32. Ingenbleek Y., and Carpentier Y.A. A prognostic inflammatory and nutritional index scoring critically ill patients. Int J Vitam Nutr Res 55 (1985) 91-101
33. Perier C., Granouillet R., Chamson A., Gonthier R., and Frey J. Nutritional markers, acute phase reactants and tissue inhibitor of matrix metalloproteinase I in elderly patients with pressure sores. Gerontology 48 (2002) 298-301